Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Oncology Conference
01/26/2022 - 07:00 AM
NEW YORK, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana " or the "Company "), a clinical-stage biopharmaceutical company developing breakthrough therapies for KRAS+ Non-Small Cell Lung Cancer (NSCLC) and transformational drug delivery technologies to enable alternative routes of immunotherapy, today announced its Chief Executive Officer and Chief Scientific Officer, Kunwar Shailubhai, Ph.D., will participate in a virtual fireside chat at the B.Riley Securities 2022 Oncology Conference on Thursday, 27 January 2022 at 4:00 p.m. EDT (U.S. and Canada) to provide Company updates.
About Tiziana Life Sciences Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For further information please contact: Hana Malik, Business Development and Investor Relations Manager +44 (0) 207 495 2379 email: info@tizianalifesciences.com
United States:Investors: Irina Koffler LifeSci Advisors Tel: (646) 970-4681ikoffler@lifesciadvisors.com
Tiziana Life Sciences Ltd
TLSA Rankings
#2682 Ranked by Stock Gains
TLSA Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
About TLSA
tiziana life sciences plc is a uk biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. the company is focused on its lead compound, milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (cdk) involved in cell division as well as a number of other protein kinases. milciclib is currently in phase ii clinical trials for thymic carcinoma in patients previously treated with chemotherapy. the company is also in clinical development of foralumab. foralumab is the only fully human engineered anti-human cd3 antibody in clinical development. this phase ii compound has potential application in a wide range of autoimmune and inflammatory diseases, such as ulcerative colitis, multiple sclerosis, type-1 diabetes (t1d), inflammatory bowel disease (ibd), psoriasis and rheumatoid arthritis, where modulation of a t-cell response is desirable. tiziana life sciences’ research